BMN-701 regulatory update

FDA granted Orphan Drug designation for BioMarin's BMN-701 (formerly ZC-701) to treat Pompe's disease. The company plans to start Phase I/II testing of BMN-701 for the indication in 1Q11. BMN-701 is a...